[1] |
Zeng Z, Zheng L, Lin J, et al. Successful bortezomib treatment in combination with dexamethasone and thalidomide for previously untreated epidural plasmacytoma[J]. Oncol Lett,2012,3(3):557-9.
|
[2] |
Leiba M, Jakubikova J, Klippel S, et al.. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents[J]. Br J Haematol, 2012,157(6):718-31.
|
[3] |
Zhen YS, Xue YC, Shao RG. Antitumor activity of the new enediyne antibiotic C1027[J]. Zhongguo Kang Sheng Su Za Zhi,1994,19(2):164-8.[甄永苏, 薛玉川, 邵荣光. 烯二 炔类新抗生素C1027的抗肿瘤作用研究[J]. 中国抗生素杂志,1994,19(2):164-8.]
|
[4] |
Zhong GS, Guo XF, Zhang SH, et al. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array[J]. Biomed Environ Sci, 2011,24(6):602-7.
|
[5] |
Zhang Q, Liu XJ, Hu L, et al. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy[J]. Int J Mol Med,2012,29(3):409-15.
|
[6] |
Zhen HY, He QH, Zhen YZ, et al.. Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc[J]. Invest New Drugs,2011,29(6):1188-97.
|
[7] |
Zhen YZ, Lin YJ, Shang BY, et al. Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase[J]. Int J Hematol,2009,90(1):44-51.
|
[8] |
Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions[J]. Endocr Rev,2001,22(2):153-83.
|
[9] |
Huang P, Han J, Hui L. MAPK signaling in inflammationassociated cancer development[J]. Protein Cell,2010,1(3):218-26.
|
[10] |
Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis[J]. IUBMB Life,2006,58(11):621-31.
|
[11] |
Wen J, Cheng HY, Feng Y, et al. p38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells[J]. Br J Haematol,2008,140(2):169-80.
|
[12] |
Zhang B,Wang X,Cai F,et al. Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation[J]. Oncol Rep,2013,29(4):1371-8.
|
[13] |
Guo R,Lin J,Xu W, et al. Hydrogen sulfi de attenuates doxorubicininduced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells [J]. Int J Mol Med,2013, 31(3):644-50.
|